We Use Cookies

This website uses cookies to optimize performance, preferences, usage and statistics. By accepting them, you consent to store on your device only the cookies that don't require consent. You can check our privacy policy page for more information.

Bridging the Gap: New Collaborations to Drive Antimicrobial Innovation

This virtual event launched the AMR Action Fund, a partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The fund will invest approximately $1 billion to ensure a robust and diverse pipeline of new medicines to treat drug-resistant infections. 

Visit www.AMRActionFund.com to learn more.

Speakers (in order of appearance):

  • David Ricks, Chairman and CEO, Eli Lilly and Company
  • Michelle McMurry-Heath, President and CEO, BIO
  • Brandon Noble, former NFL player
  • Stephen J. Ubl, President and CEO, PhRMA
  • Ken Frazier, Chairman and CEO, Merck
  • Albert Bourla, Chairman and CEO, Pfizer
  • Priscilla VanderVeer, Vice President, PhRMA
  • ADM Brett P. Giroir, MD, Assistant Secretary for Health
  • Senator Bob Casey (D-PA)
  • Senator Bill Cassidy, MD (R-LA)
  • Scott Gottlieb, resident fellow, American Enterprise Institute – moderator
  • Helen Boucher, MD, board member and treasurer, Infectious Disease Society of America
  • Kathy Talkington, director, Health Programs, The Pew Charitable Trusts
  • Kevin Outterson, executive director and principal investigator, CARB-X
  • Ramani Varanasi, founder/president/CEO, X-Biotix
  • Michael Boyle, MD, president and CEO, Cystic Fibrosis Foundation

Bridging the Gap: New Collaborations to Drive Antimicrobial Innovation Event Video

A virtual event hosted by PhRMA, IFPMA and BIO announced the launch of the AMR Action Fund, a partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The fund will invest approximately $1 billion to ensure a robust and diverse pipeline of new medicines to treat drug-resistant infections.

Watch the video of the event here.